Updated Date: Mon, 13 Feb 2023 00:00:00 EST

Updated Date: Mon, 13 Feb 2023 00:00:00 EST

Updated Date: Mon, 13 Feb 2023 00:00:00 EST

Updated Date: Mon, 13 Feb 2023 00:00:00 EST

VLA1553 is a single-dose, live-attenuated vaccine candidate targeting the highly dangerous chikungunya virus

Research concerns the effect of niraparib when combined with abiraterone acetate plus prednisone

In a potential game changer for the treatment of superbugs, a new class of antibiotics was developed that […]

Research concerning candidate VLA15 has been discontinued across certain trial sites

Company has reported strong momentum among the early-stage businesses it invested in last year

Updated Date: Thu, 09 Feb 2023 00:00:00 EST